NASDAQ
87.16USD
+14.18 (+19.43%)
We have scored 10 news catalysts on Kiniksa Pharmaceuticals International, plc (KNSA) over the past 12 months. The biggest single-day move next to one of them came Jul 28, 2026, when KNSA closed +25.0%: “Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates”. Coverage across the window leans positive (average ticker sentiment +0.55). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
6.7B
P/E
—
EPS
—
Beta
0.09
52W range
35.2-88
Day range
82.26–88.03
Open
84.52
Prev close
72.98
Volume
908.5K
Avg volume
711.3K
Dividend
0.00
IPO
2018-05-24
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Kiniksa Pharmaceuticals International, plc — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for KNSA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
